Affymetrix Sees 'Opportunity' for Diagnostics Business in Increased FDA Oversight of LDTs
September 21, 2010
Affymetrix Sees 'Opportunity' for Diagnostics Business in Increased FDA Oversight of LDTs
An Affy official noted that several assays that run on its FDA-approved platform have received clearance in the past, a fact that may give it an edge, or at least a head start, in a more-regulated molecular diagnostics environment.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.